Ogura, Suguru
Tameda, Masahiko
Sugimoto, Kazushi
Ikejiri, Makoto
Usui, Masanobu
Ito, Masaaki
Takei, Yoshiyuki
Article History
Received: 24 July 2018
Accepted: 23 April 2019
First Online: 2 May 2019
Ethics approval and consent to participate
: This study was approved by the Institutional Review Board of Mie University Hospital. The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki, as reflected in the a priori approval by the institution’s human research committee.
: Written informed consent was obtained from each patient included in the study.
: Masaaki Ito received honoraria for lecture fees from Daiichi Sankyo Co., Ltd., Bayer Yakuhin, Ltd. and Takeda Pharmaceutical Co., Ltd., and departmental scholarship funds from Bristol-Myers Squibb, MSD K.K., Shionogi & Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd. and Daiichi Sankyo Co., Ltd.Yoshiyuki Takei received honoraria for lecture fees from Otsuka Pharmaceutical Co., Ltd. and departmental scholarship funds from Astellas Pharma Inc., Eisai Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Takeda Pharmaceutical Co., Ltd., Suntory Global Innovation Center Ltd. and Kyokuto Pharmaceutical Industrial Co. Ltd.The companies associated with this funding were not involved in the preparation of the manuscript or the decision to publish the present study. The other authors declare no conflicts of interest in association with the present study.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.